14 Two therapeutic strategies currently exist to overcome the short half-life of incretin hormones and pharmacologically augment the incretin effect: 1) inject GLP-1 receptor agonists that are resistant to degradation by the DPP-4 enzyme and 2) orally administer DPP-4 inhibitors that delay the enzymatic degradation of naturally secreted incretin hormones ( Figure 2 )
Try: Power naps Guided meditation Laying down in silence 6
Waheed SM, Ghosh A, Chakravarti R, Biswas A, Haque MM, Panda K, et al
Its normal to have questions or concerns at various parts of your journey
SEMA, como tratamiento de la obesidad, ha mostrado efectos nefroprotectores con disminucin del 22% del objetivo renal compuesto en el estudio SELECT33 en pacientes sin diabetes, abogando por la utilidad de SEMA en el tratamiento del sndrome cardio-reno-metablico